This is the London Secure Data Environment (SDE) Data Use Register. It includes all projects that have received approval to access datasets within the London SDE datasets since December 2025.
Research teams need to apply to access the datasets. Applications are first reviewed by a pan-London group called Independent Information Access Group (IIAG), with clinical and public representatives from each of London’s Integrated Care Systems (ICS). The IIAG issues a recommendation to the Data Access Committee (DAC) within the relevant ICS, which then decides if an application is approved or not. Each ICS-level DAC represents a different area of London and includes representatives of health and care organisations and patient representatives.
Information about projects approved prior to December 2025 can be found here.
Research teams interested in applying for approval to access the London SDE datasets can contact: research.onelondon@nhs.net
This Data User Register is a beta release. It has been co-developed with users and members of the public to provide information about approved projects in a clear and accessible way. Work with users and the public to further develop the Register will continue throughout 2026/27.
Comorbidities and changes in the health and well-being of people who are at risk of developing dementia and exploring longitudinal electronic health care records at the level of the UK population can help us understand how these conditions relate to one another and interconnect, and what other lifestyle or historical factors might play a part.
Relevant healthcare data to attempt to detect/ evidence exacerbations of illnesses relating to changes to the air quality in Westminster and to monitor activity to see if local policy changes targeting air quality have an impact on exacerbations.
The new CRM clinic model targets adult patients (aged 20–80) identified as having high or intermediate risk for cardiovascular disease (CVD), chronic kidney disease (CKD), diabetes, or obesity, using a bespoke EMIS search logic.
We will look at which medicines are being prescribed, how they are used over time, and how well they work for different groups of patients. This includes treatments like budesonide and 5-ASAs, which are commonly used to help control inflammation and maintain remission.
If we are able to evidence a reduction in hospital admissions and LAS calls this will inform how we utilise our resources. In other words, this will help decide how and when to rollout the service to other neighbourhoods
The outcome of the project will also enable us to make changes to how we deliver the ICAP service in order to have the most positive impact on patients. For example, we may need to increase the nursing input and reduce the social
work input or vice versa
This project aims to investigate the long-term risk of prediabetes among statin users, identify the proportion of this risk attributable to statin use, and examine how this component influences the overall long-term risk of prediabetes. We want to enhance the coherence of statin-associated lipid-lowering strategies, further improve the achievement rate of lipid-lowering goals, and reduce the burden on both individuals and society by developing a statin-induced prediabetes prediction model.
